Home ›
Leukemia Trials ›
NCT06394011
Study of VA Combined With HAAG Regimen in Newly Diagnosed Intermediate and High-risk AML Patients
The purpose of this study is to evaluate the efficacy and safety of VA combined with HAAG in the induction treatment of newly diagnosed acute myeloid leukemia.
Trial Details
NCT ID NCT06394011
Phase PHASE2
Sponsor The First Affiliated Hospital of Soochow University
Status RECRUITING
Cancer Type Leukemia
Interventions venetoclax, azacitidine and HAAG regimen
Locations (sample) Suzhou, Jiangsu, China|31.30408,120.59538
Key Eligibility Criteria
Newly diagnosed intermediate and high-risk AML according to the WHO (2022) classification of acute myeloid leukemia (non-APL). Age 18-65. ECOG score: 0-2. No history of previous chemotherapy or target therapy.
For full eligibility, visit ClinicalTrials.gov .
Check If You May Be Eligible
Trialify translates complex eligibility criteria into plain yes-or-no questions to help you understand if this trial might be right for you.
Find Leukemia Trials on Trialify →